Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 4/20 | 0.60 |
| ▸ | CYCS | P99999 | 4/20 | 0.59 |
| ▸ | STAT3 | P40763 | 1/20 | 0.57 |
| ▸ | STAT1 | P42224 | 1/20 | 0.57 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11339474 | 0.89 | TOP1 (0.75) | TOP1CYCSSTAT3STAT1ENPP2 | |
| SCHEMBL22332272 | 0.87 | TOP1 (0.70) | TOP1CYCSSTAT3STAT1ENPP2 | |
| SCHEMBL17894094 | 0.85 | TOP1 (0.75) | TOP1CYCSSTAT3STAT1ENPP2 | |
| SCHEMBL140681 | 0.85 | TOP1 (0.67) | TOP1CYCSSTAT3STAT1ENPP2 | |
| SCHEMBL11334086 | 0.84 | TOP1 (0.65) | TOP1CYCSSTAT3STAT1ENPP2 | |
| SCHEMBL28919688 | 0.84 | TOP1 (0.65) | TOP1CYCSSTAT3STAT1ENPP2 | |
| SCHEMBL24270402 | 0.80 | STAT3 (0.82) | TOP1CYCSSTAT3STAT1ENPP2 | |
| SCHEMBL1224432 | 0.80 | STAT3 (0.86) | TOP1CYCSSTAT3STAT1ENPP2 | |
| SCHEMBL31550992 | 0.80 | STAT3 (0.86) | TOP1CYCSSTAT3STAT1ENPP2 | |
| SCHEMBL30293296 | 0.80 | STAT3 (0.86) | TOP1CYCSSTAT3STAT1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11826426-B2 | Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof | THE UNIVERSITY OF CHICAGO (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230293698-A1 | METAL-ORGANIC FRAMEWORKS DELIVER SMALL MOLECULES AND BIOMACROMOLECULES FOR CANCER IMMUNOTHERAPY | UNIV CHICAGO (US) | 2023-09-21 | — | — | US | disclosed |
| US-20200254095-A1 | NANOSCALE METAL-ORGANIC LAYERS AND METAL-ORGANIC NANOPLATES FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RADIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF | THE UNIVERSITY OF CHICAGO | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293698-A1 | METAL-ORGANIC FRAMEWORKS DELIVER SMALL MOLECULES AND BIOMACROMOLECULES FOR CANCER IMMUNOTHERAPY | ORC3, RBM3, RNMT | TOP1 266/4885CYCS 2330/4885STAT3 1293/4885 |
| US-11826426-B2 | Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof | CD274, PDCD1LG2, PDCD1 | TOP1 166/4885CYCS 2415/4885STAT3 2688/4885 |
| US-20200254095-A1 | NANOSCALE METAL-ORGANIC LAYERS AND METAL-ORGANIC NANOPLATES FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RADIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF | CD274, PDCD1LG2, PDCD1 | TOP1 166/4885CYCS 2415/4885STAT3 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.